Serum arylhydrocarbon receptor transactivating activity is elevated in type 2 diabetic patients with diabetic nephropathy

Journal of Diabetes Investigation

Volumn 4, Issue 5, 2013, Pages 483-491

  Kim, Jin Taek ^a   Kim, Sang Soo ^b   Jun, Dae Won ^c   Hwang, Young Hwan ^a   Park, Wook Ha ^d   Pak, Youngmi Kim ^d   Lee, Hong Kyu ^a  

^a Eulji University   (South Korea)

^b Eulji Medi Bio Research Institute   (South Korea)

^c Hanyang University   (South Korea)

^d Kyung Hee University Hospital   (South Korea)

Author keywords

Aryl hydrocarbon receptor ligands; Diabetic nephropathy; Persistent organic pollutants

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; AROMATIC HYDROCARBON RECEPTOR;

ADULT; ALBUMINURIA; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; KIDNEY FAILURE; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN URINE LEVEL; RISK ASSESSMENT; TRANSACTIVATION;

EID: 84884209558     PISSN: 20401116     EISSN: 20401124     Source Type: Journal    
DOI: 10.1111/jdi.12081     Document Type: Article

References (44)

1. Girach A, Manner D, Porta M. Diabetic microvascular complications: can patients at risk be identified? A review. Int J Clin Pract 2006; 60: 1471-1483.
2. Hasslacher C, Ritz E, Wahl P, et al. Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 1989; 4: 859-863.
3. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-986.
4. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853.
5. Lee DH, Lee IK, Song K, et al. A strong dose-response relation between serum concentrations of persistent organic pollutants and diabetes: results from the National Health and Examination Survey 1999-2002. Diabetes Care 2006; 29: 1638-1644.
6. Lee DH, Jacobs DR Jr, Steffes M. Association of organochlorine pesticides with peripheral neuropathy in patients with diabetes or impaired fasting glucose. Diabetes 2008; 57: 3108-3111.
7. Han D, Nagy SR, Denison MS. Comparison of recombinant cell bioassays for the detection of Ah receptor agonists. BioFactors 2004; 20: 11-22.
8. Park WH, Jun DW, Kim JT, et al. Novel cell-based assay reveals associations of circulating serum AhR-ligands with metabolic syndrome and mitochondrial dysfunction. BioFactors 2013; ????: ????-????.
9. Everett CJ, Frithsen IL, Diaz VA, et al. Association of a polychlorinated dibenzo-p-dioxin, a polychlorinated biphenyl, and DDT with diabetes in the 1999-2002 National Health and Nutrition Examination Survey. Environ Res 2007; 103: 413-418.
10. Ha MH, Lee DH, Son HK, et al. Association between serum concentrations of persistent organic pollutants and prevalence of newly diagnosed hypertension: results from the National Health and Nutrition Examination Survey 1999-2002. J Hum Hypertens 2009; 23: 274-286.
11. Lee DH, Lee IK, Jin SH, et al. Association between serum concentrations of persistent organic pollutants and insulin resistance among nondiabetic adults: results from the National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 2007; 30: 622-628.
12. Wang SL, Tsai PC, Yang CY, et al. Increased risk of diabetes and polychlorinated biphenyls and dioxins: a 24-year follow-up study of the Yucheng cohort. Diabetes Care 2008; 31: 1574-1579.
13. Everett CJ, Matheson EM. Biomarkers of pesticide exposure and diabetes in the 1999-2004 National Health and Nutrition Examination Survey. Environ Int 2010; 36: 398-401.
14. Lee DH, Lee IK, Steffes M, et al. Extended analyses of the association between serum concentrations of persistent organic pollutants and diabetes. Diabetes Care 2007; 30: 1596-1598.
15. Kashiwagi A, Kasuga M, Araki E, et al. International clinical harmonization of glycated hemoglobin in Japan: from Japan Diabetes Society to National Glycohemoglobin Standardization Program values. J Diabetes Invest 2012; 3: 39-40.
16. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
17. Collins AJ, Foley RN, Herzog C, et al. US Renal Data System 2010 Annual Data Report. Am J Kidney Dis 2011; 57: e1-e526.
18. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906.
19. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
20. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
21. Osterby R, Gundersen HJ, Horlyck A, et al. Diabetic glomerulopathy. Structural characteristics of the early and advanced stages. Diabetes 1983; 32(Suppl 2): 79-82.
22. Mauer SM, Steffes MW, Brown DM. The kidney in diabetes. Am J Med 1981; 70: 603-612.
23. Bilous RW, Mauer SM, Basgen JM, et al. Estimation of mean glomerular volume in patients with insulin-dependent diabetes mellitus. Kidney Int 1987; 32: 930-932.
24. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982; 72: 375-380.
25. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999; 48: 1-9.
26. Raj DS, Choudhury D, Welbourne TC, et al. Advanced glycation end products: a Nephrologist's perspective. Am J Kidney Dis 2000; 35: 365-380.
27. Wolf G, Ziyadeh FN. The role of angiotensin II in diabetic nephropathy: emphasis on nonhemodynamic mechanisms. Am J Kidney Dis 1997; 29: 153-163.
28. Schreiber BD, Hughes ML, Groggel GC. Insulin-like growth factor-1 stimulates production of mesangial cell matrix components. Clin Nephrol 1995; 43: 368-374.
29. Cooper ME, Vranes D, Youssef S, et al. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes. Diabetes 1999; 48: 2229-2239.
30. Kern PA, Fishman RB, Song W, et al. The effect of 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD) on oxidative enzymes in adipocytes and liver. Toxicology 2002; 171: 117-125.
31. Bagchi D, Balmoori J, Bagchi M, et al. Comparative effects of TCDD, endrin, naphthalene and chromium (VI) on oxidative stress and tissue damage in the liver and brain tissues of mice. Toxicology 2002; 175: 73-82.
32. Shen D, Dalton TP, Nebert DW, et al. Glutathione redox state regulates mitochondrial reactive oxygen production. J Biol Chem 2005; 280: 25305-25312.
33. Stohs SJ. Oxidative stress induced by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin (TCDD). Free Radic Biol Med 1990; 9: 79-90.
34. Stohs SJ, Al-Bayati ZF, Hassan MQ, et al. Glutathione peroxidase and reactive oxygen species in TCDD-induced lipid peroxidation. Adv Exp Med Biol 1986; 197: 357-365.
35. Forgacs AL, Burgoon LD, Lynn SG, et al. Effects of TCDD on the expression of nuclear encoded mitochondrial genes. Toxicol Appl Pharmacol 2010; 246: 58-65.
36. Petersen KF, Befroy D, Dufour S, et al. Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 2003; 300: 1140-1142.
37. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005; 307: 384-387.
38. Hillegass JM, Murphy KA, Villano CM, et al. The impact of aryl hydrocarbon receptor signaling on matrix metabolism: implications for development and disease. Biol Chem 2006; 387: 1159-1173.
39. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 2007; 8: 221-233.
40. Inada A, Nagai K, Arai H, et al. Establishment of a diabetic mouse model with progressive diabetic nephropathy. Am J Pathol 2005; 167: 327-336.
41. McLennan SV, Martell SK, Yue DK. Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 2002; 51: 2612-2618.
42. Han SY, Jee YH, Han KH, et al. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy. Nephrol Dial Transplant 2006; 21: 2406-2416.
43. Opitz CA, Litzenburger UM, Sahm F, et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 2011; 478: 197-203.
44. Zhang S, Qin C, Safe SH. Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ Health Perspect 2003; 111: 1877-1882.